These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 38888299)

  • 41. Conjugation site modulates the in vivo stability and therapeutic activity of antibody-drug conjugates.
    Shen BQ; Xu K; Liu L; Raab H; Bhakta S; Kenrick M; Parsons-Reponte KL; Tien J; Yu SF; Mai E; Li D; Tibbitts J; Baudys J; Saad OM; Scales SJ; McDonald PJ; Hass PE; Eigenbrot C; Nguyen T; Solis WA; Fuji RN; Flagella KM; Patel D; Spencer SD; Khawli LA; Ebens A; Wong WL; Vandlen R; Kaur S; Sliwkowski MX; Scheller RH; Polakis P; Junutula JR
    Nat Biotechnol; 2012 Jan; 30(2):184-9. PubMed ID: 22267010
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Targeting ketone drugs towards transport by the intestinal peptide transporter, PepT1.
    Foley D; Bailey P; Pieri M; Meredith D
    Org Biomol Chem; 2009 Mar; 7(6):1064-7. PubMed ID: 19262922
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Enzyme-Agnostic Lysosomal Screen Identifies New Legumain-Cleavable ADC Linkers.
    Miller JT; Vitro CN; Fang S; Benjamin SR; Tumey LN
    Bioconjug Chem; 2021 Apr; 32(4):842-858. PubMed ID: 33788548
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Thiol activated prodrugs of sulfur dioxide (SO2) as MRSA inhibitors.
    Pardeshi KA; Malwal SR; Banerjee A; Lahiri S; Rangarajan R; Chakrapani H
    Bioorg Med Chem Lett; 2015 Jul; 25(13):2694-7. PubMed ID: 25981687
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Novel linkers and connections for antibody-drug conjugates to treat cancer and infectious disease.
    Pillow TH
    Pharm Pat Anal; 2017 Jan; 6(1):25-33. PubMed ID: 28155578
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Design and Validation of Linkers for Site-Specific Preparation of Antibody-Drug Conjugates Carrying Multiple Drug Copies Per Cysteine Conjugation Site.
    Kumar A; Mao S; Dimasi N; Gao C
    Int J Mol Sci; 2020 Sep; 21(18):. PubMed ID: 32961794
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Site-specific traceless coupling of potent cytotoxic drugs to recombinant antibodies for pharmacodelivery.
    Casi G; Huguenin-Dezot N; Zuberbühler K; Scheuermann J; Neri D
    J Am Chem Soc; 2012 Apr; 134(13):5887-92. PubMed ID: 22394212
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Assembly of pH-Responsive Antibody-Drug-Inspired Conjugates.
    Raabe M; Heck AJ; Führer S; Schauenburg D; Pieszka M; Wang T; Zegota MM; Nuhn L; Ng DYW; Kuan SL; Weil T
    Macromol Biosci; 2022 Feb; 22(2):e2100299. PubMed ID: 34791790
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Molecular Basis of Valine-Citrulline-PABC Linker Instability in Site-Specific ADCs and Its Mitigation by Linker Design.
    Dorywalska M; Dushin R; Moine L; Farias SE; Zhou D; Navaratnam T; Lui V; Hasa-Moreno A; Casas MG; Tran TT; Delaria K; Liu SH; Foletti D; O'Donnell CJ; Pons J; Shelton DL; Rajpal A; Strop P
    Mol Cancer Ther; 2016 May; 15(5):958-70. PubMed ID: 26944918
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Sensitive ELISA Method for the Measurement of Catabolites of Antibody-Drug Conjugates (ADCs) in Target Cancer Cells.
    Salomon PL; Singh R
    Mol Pharm; 2015 Jun; 12(6):1752-61. PubMed ID: 25738394
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Addition of dithiols to bis-ynones: development of a versatile platform for the synthesis of polyketide natural products.
    Sneddon HF; Gaunt MJ; Ley SV
    Org Lett; 2003 Apr; 5(7):1147-50. PubMed ID: 12659595
    [TBL] [Abstract][Full Text] [Related]  

  • 52. CBTF: new amine-to-thiol coupling reagent for preparation of antibody conjugates with increased plasma stability.
    Kolodych S; Koniev O; Baatarkhuu Z; Bonnefoy JY; Debaene F; Cianférani S; Van Dorsselaer A; Wagner A
    Bioconjug Chem; 2015 Feb; 26(2):197-200. PubMed ID: 25614935
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Contribution of linker stability to the activities of anticancer immunoconjugates.
    Alley SC; Benjamin DR; Jeffrey SC; Okeley NM; Meyer DL; Sanderson RJ; Senter PD
    Bioconjug Chem; 2008 Mar; 19(3):759-65. PubMed ID: 18314937
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Characterization of drug load variants in a thiol linked antibody-drug conjugate using multidimensional chromatography.
    Gilroy JJ; Eakin CM
    J Chromatogr B Analyt Technol Biomed Life Sci; 2017 Aug; 1060():182-189. PubMed ID: 28622622
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Antibody drug conjugates: design and selection of linker, payload and conjugation chemistry.
    McCombs JR; Owen SC
    AAPS J; 2015 Mar; 17(2):339-51. PubMed ID: 25604608
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Bioconjugation through Mesitylene Thiol Alkylation.
    Ramos-Tomillero I; Perez-Chacon G; Somovilla-Crespo B; Sanchez-Madrid F; Domínguez JM; Cuevas C; Zapata JM; Rodríguez H; Albericio F
    Bioconjug Chem; 2018 Apr; 29(4):1199-1208. PubMed ID: 29433317
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Diazaborines Are a Versatile Platform to Develop ROS-Responsive Antibody Drug Conjugates*.
    António JPM; Carvalho JI; André AS; Dias JNR; Aguiar SI; Faustino H; Lopes RMRM; Veiros LF; Bernardes GJL; da Silva FA; Gois PMP
    Angew Chem Int Ed Engl; 2021 Dec; 60(49):25914-25921. PubMed ID: 34741376
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Discovery of Pyrophosphate Diesters as Tunable, Soluble, and Bioorthogonal Linkers for Site-Specific Antibody-Drug Conjugates.
    Kern JC; Cancilla M; Dooney D; Kwasnjuk K; Zhang R; Beaumont M; Figueroa I; Hsieh S; Liang L; Tomazela D; Zhang J; Brandish PE; Palmieri A; Stivers P; Cheng M; Feng G; Geda P; Shah S; Beck A; Bresson D; Firdos J; Gately D; Knudsen N; Manibusan A; Schultz PG; Sun Y; Garbaccio RM
    J Am Chem Soc; 2016 Feb; 138(4):1430-45. PubMed ID: 26745435
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Polyethylene glycol-based linkers as hydrophilicity reservoir for antibody-drug conjugates.
    Tedeschini T; Campara B; Grigoletto A; Bellini M; Salvalaio M; Matsuno Y; Suzuki A; Yoshioka H; Pasut G
    J Control Release; 2021 Sep; 337():431-447. PubMed ID: 34329685
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Predictable and tunable half-life extension of therapeutic agents by controlled chemical release from macromolecular conjugates.
    Santi DV; Schneider EL; Reid R; Robinson L; Ashley GW
    Proc Natl Acad Sci U S A; 2012 Apr; 109(16):6211-6. PubMed ID: 22474378
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.